All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – Freshly installed Commissioner Jiao Hong of the China National Drug Administration, formerly the CFDA, voiced the agency's plans to streamline review and approval of new drugs, encourage innovation, improve capacity to take a science-based approach, deepen industry's quality control efforts and step up monitoring of adverse events.